Healthcare
Live Price
Offline$0.0007
+0.00% today
1Y Change
-93.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Remedent, Inc. (REMI) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 93.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +14.2%, EPS growth of +81.7%, a dividend yield of 0.0%. What stands out right now is revenue +14.2%, EPS +81.7%, free cash flow -145.9% with operating margin -12.5% and ROIC -5.0%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines REMI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
REMI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
REMI Max Drawdown
-98.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for REMI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.1M
+3.4% YoY
FY Net Income
-$854.3K
-423.8% YoY
Free Cash Flow
$101.5K
+5800.5% YoY
Revenue Growth
+14.2%
EPS Growth
+81.7%
Gross Margin
61.2%
Net Margin
-27.8%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 986K | 864K | 1M | 1M | 1M |
| Gross Profit | 603K | 506K | 1M | 579K | 742K |
| Operating Income | -123K | -283K | 317K | -32K | -480K |
| EBITDA | -215K | -1M | -154K | -102K | -767K |
| Net Income | -274K | -1M | -257K | -163K | -854K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 43K | 105K | 174K | 78K | 115K |
| Total Assets | 5M | 6M | 7M | 7M | 8M |
| Total Liabilities | 3M | 3M | 3M | 3M | 3M |
| Shareholder Equity | 2M | 3M | 4M | 4M | 5M |
| Total Debt | 15K | 0 | 0 | 5K | 5K |
| Net Debt | -43K | -105K | -174K | -72K | -109K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
102K
+5800.5% YoY
Capital Expenditures
0
Free Cash Flow
102K
+5800.5% YoY
Key ratios
Gross Margin
61.2%
Operating Margin
-12.5%
Net Margin
-27.8%
ROE
-11.3%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.